

BENZENE

VOLUME 120



This publication represents the views and expert
opinions of an IARC Working Group on the
Evaluation of Carcinogenic Risks to Humans,
which met in Lyon, 10–17 October 2017

LYON, FRANCE - 2018

IARC MONOGRAPHS
ON THE EVALUATION
OF CARCINOGENIC RISKS
TO HUMANS

CONTENTS

NOTE TO THE READER	1
LIST OF PARTICIPANTS	3
PREAMBLE	9
A. GENERAL PRINCIPLES AND PROCEDURES	9
1. Background	9
2. Objective and scope	10
3. Selection of agents for review	11
4. Data for the <i>Monographs</i>	12
5. Meeting participants	12
6. Working procedures	13
B. SCIENTIFIC REVIEW AND EVALUATION	14
1. Exposure data	15
2. Studies of cancer in humans	16
3. Studies of cancer in experimental animals	20
4. Mechanistic and other relevant data	23
5. Summary	26
6. Evaluation and rationale	27
References	31
GENERAL REMARKS	33
1. EXPOSURE DATA	37
1.1 Identification of the agent	37
1.2 Production and use	38
1.3 Measurement and analysis	39
1.4 Occurrence and exposure	43
1.5 Regulations and guidelines	76
1.6 Exposure assessment methods in epidemiological studies of cancer	79
References	92

2. CANCER IN HUMANS	105
2.1 Adult leukaemia	105
2.2 Adult lymphoma	124
2.3 Childhood cancer	137
2.4 Other cancers	149
2.5 Quantitative data	163
References	167
3. CANCER IN EXPERIMENTAL ANIMALS	175
3.1 Mouse	175
3.2 Rat	197
3.3 Genetically modified animals	209
References	216
4. MECHANISTIC AND OTHER RELEVANT DATA	219
4.1 Toxicokinetic data	219
4.2 Mechanisms of carcinogenesis	225
4.3 Data relevant to comparisons across agents and end-points	261
4.4 Observed exposure–response relationships in mechanistic studies	266
References	269
5. SUMMARY OF DATA REPORTED	289
5.1 Exposure data	289
5.2 Human carcinogenicity data	290
5.3 Animal carcinogenicity data	293
5.4 Mechanistic and other relevant data	295
6. EVALUATION AND RATIONALE	297
6.1 Cancer in humans	297
6.2 Cancer in experimental animals	297
6.3 Overall evaluation	297
6.4 Rationale	297
LIST OF ABBREVIATIONS	299
ANNEX 1. SUPPLEMENTAL MATERIAL FOR TOXCAST/TOX21	301